Bats are notorious reservoirs of diverse, potentially zoonotic viruses, exemplified by the 20 evolutionarily distinct, influenza A-like viruses H17N10 and H18N11 (BatIVs). The surface 21 glycoproteins [haemagglutinin (H) and neuraminidase (N)] of BatIVs neither bind nor cleave 22 sialic acid receptors, which suggests that these viruses employ cell attachment and entry 23 mechanisms that differ from those of classical influenza A viruses (IAVs). Identifying the 24 cellular factors that mediate entry and determine susceptibility to infection will help assess 25 the host range of BatIVs. Here, we investigated a range of cell lines from different species for 26 their susceptibility to infection by pseudotyped viruses (PV) bearing bat H17 and/or N10 27 envelope glycoproteins. We show that a number of human haematopoietic cancer cell lines 28 and the canine kidney MDCK II (but not MDCK I) cells are susceptible to H17-pseudotypes 29 (H17-PV). We observed with microarrays and qRT-PCR that the dog leukocyte antigen DLA-30 DRA mRNA is over expressed in late passaged parental MDCK and commercial MDCK II cells, 31 compared to early passaged parental MDCK and MDCK I cells, respectively. The human 32 orthologue HLA-DRA encodes the alpha subunit of the MHC class II HLA-DR antigen-binding 33 heterodimer. Small interfering RNA-or neutralizing antibody-targeting HLA-DRA, drastically 34 reduced the susceptibility of Raji B cells to H17-PV. Conversely, over expression of HLA-DRA 35 and its paralogue HLA-DRB1 on the surface of the unsusceptible HEK293T/17 cells conferred 36 susceptibility to H17-PV. The identification of HLA-DR as an H17N10 entry mediator will 37
to accommodate SA 2, 15, 17 . The cell receptors for the BatIVs are as yet unidentified, but they 79 are clearly not SA moieties, a conclusion reached by several studies 15, 18, 19 . Furthermore, bat 80 N10 and N11 are structurally similar to classical NAs but lack conserved amino acids for SA 81 binding and cleavage 2, 16, 17 and do not exhibit typical neuraminidase activity 18, 20 . Initial 82 efforts to isolate infectious BatIVs directly from bats have failed, mainly because the receptors 83 were unknown and susceptible cell lines were unavailable 21, 22, 23 . Attempts to circumvent 84 these limitations have included H17-or H18-pseudotyped vesicular stomatitis virus (VSV 19, 85 24 ), engineered BatIV/IAV chimeric viruses 23, 25 , and authentic BatIVs reconstructed using 86 reverse genetics 26 . H17-VSV was able to infect bat cell lines (EidNi, HypNi, and EpoNi) but 87 only a few, common cell lines of flightless mammals, including some of human glioblastoma and SK-Mel-28 melanoma) and canine (RIE1495 and MDCK II kidney) origin 19, 24, 89 26 . These cells could also be infected with reconstructed H17N10 and H18N11 viruses 26 . The 90 ability of BatIVs to infect mammalian cell lines in vitro, and their unconventional features, 91 raised concerns about their zoonotic and epidemic potential. Identifying the BatIV cell surface 92 receptors and delineating the mechanistic basis of the host-virus interaction are key to 93 assessing their potential host range and public health significance. 94 95 HIV-1 derived-pseudotypes bearing heterologous envelope proteins (PV) have been used 96 widely for the assessment of cellular tropism and the identification of cellular receptors or 97 attachment factors for a range of viruses 27, 28, 29, 30, 31 . Such pseudotypes have proved a 98 reliable model to study the capacity of H17N10 for entry into various cell lines 27, 32 . Using this 99 approach, we have shown that H17-PV, and H17N10-PV (A/little yellow-shouldered 100 bat/Guatemala/060/2011) are recovered from producer HEK293T/17 cells exclusively in the 101 presence of the human airway trypsin-like protease (HAT) or the transmembrane protease, 102 serine 2 (TMPRSS2) (Fig. 1a ) 32 . In this study, a panel (n=35; Supplementary material 1) of cell 103 lines from different tissues and species were challenged with H17-and/or N10-PV to study the distribution of the H17N10 receptor(s) (Fig. 1b) . Efficiency of infections with PV was 105 quantified (after 48 h) by the expression of a firefly luciferase (FLuc) reporter gene encoded 106 by the lentiviral genome. Parallel infections were conducted with PV bearing either classical 107 H5 (H5-PV; A/Vietnam/1194/2004; H5N1 clade 1) or VSV-G (VSV-G-PV) glycoproteins (the 108 latter displaying very broad tropism) as positive controls to eliminate possible post-binding 109 blockage factors. HIV particles produced in the absence of a viral envelope protein (Δ-env) 110 served as a negative control. H17-PV displayed highly limited host and species cell tropism, 111
suggesting that the H17 cellular receptor(s) are not ubiquitous ( Fig. 1b ). Of note, the bat cell 112 lines (lung & kidney) from S. lilium in which H17N10 was discovered, were not susceptible to 113
PV. This implies that expression of the H17-putative receptor(s) and/or viral entry-related 114 host factors was either lost during immortalisation or is tissue-type restricted. Conversely, we 115
show that the dog epithelial kidney MDCK II (unlike MDCK I) cells are susceptible to H17-PV 116 with titers comparable to those of control VSV-G-and H5-PV in the range of 10 6 to 10 7 117 RLU/ml ( Fig. 1c ). They were not susceptible to PV expressing N10 alone and co-expression of 118 N10 with H17 did not improve infection of MDCK II (Fig. 1c ), which suggests that N10 has a 119 dispensable role in viral entry (in vitro). To characterise the H17 putative receptors, MDCK II 120 cells were either pre-treated with neuraminidase, tunicamycin or pronase or treated with 121 ammonium chloride before infection with H17-PV. Infectivity with H17-and H5-PVs, as well 122 as cytotoxicity (by trypan blue exclusion), were assayed 24 h post treatment ( Fig. 1d ). Pre-123 treatment of MDCK II cells with neuraminidase from Clostridium perfrigens (1-100 mU), which 124 cleaves cell surface SA, reduced H5-PV infection by 68-86% but did not significantly affect 125 infection by H17-PV, supporting the notion that SA are not the cell surface receptors for 126 H17 19, 26 . Classical IAVs primarily enter cells via endocytosis followed by endosomal fusion 127 triggered by low pH. Treatment of MDCK II cells with the pH neutralising agent ammonium 128 chloride (1-100 mM) abolished luciferase activity for both H5-and H17-PV, demonstrating 129 that entry of H17, like IAVs, into target cells is pH-dependent. Similar results were obtained in RIE1495 cells 32 . Entry of H17-PV was more susceptible to pre-treatment of MDCK II cells with 131 proteases or tunicamycin (an inhibitor of N-glycosylation) than was entry of H5-PV (being 132 reduced by up to 72 and 78%, compared to 45 and 20%, respectively), suggesting that the 133 H17-cellular receptor(s) may be a glycosylated protein, in line with previous proposals 19 . 134 135 MDCK I and II represent early and late passaged cells from the same parental NBL-2 cell line 136 (CCL-34, ATCC). MDCK are valuable cell lines in studies of viruses, cell-cell junctions and 137 epithelial differentiation but consist of heterogeneous cell populations and their phenotypes 138 vary significantly between user laboratories 33 . In addressing the factors that permit infection 139 of H17-PV in late passaged MDCK II cells, we considered that parental NBL-2 cells undergo 140 passage number-dependent phenotypic changes that may be reflected at transcriptional level. 141
The phenotypic transition of NBL-2 cells to early and late MDCK cells was investigated using 142 the Affymetrix canine microarray 2.0 (E-GEOD-14837; passages 8 and 21 respectively). The 143 microarray analysis identified 17 differentially regulated transcripts: 12 up-regulated and 5 144 down-regulated in late-compared to early-passaged cells (Fig. 2a ). The current prevalent 145 hypothesis is that single or multiple cell surface molecules are essential for the initial 146 attachment and uptake of enveloped viruses into cells 34, 35 . Therefore, we surveyed the 147 differentially regulated transcripts for encoded, surface-anchored proteins using a combined 148 analysis of: available Gene Ontology annotations, existing literature as well as transmembrane 149 protein domain and subcellular localisation prediction algorithms (Phobius, TMHMM and 150 DeepLoc). The analysis identified the dog leukocyte antigen class II DR α-chain (DLA-DRA) as 151 the only transcript, encoding a membrane protein, over-expressed in late, compared to early, 152 passage MDCK cells (full data in Supplementary material 2). Significant over-expression of 153 DLA-DRA (and its paralogue DLA-DRB1) was also confirmed (by qRT-PCR) in MDCK II 154 compared to MDCK I cells ( Fig. 2b) . 155 DLA-DRA is a well-conserved orthologue of the human leukocyte antigen class II DR α-chain 157 (HLA-DRA) (∼90% amino acid identity between canine, human and Desmodus rotundus bat 158 ectodomains; Supplementary material 3). In humans, MHC-II molecules occur as three highly 159 polymorphic isotypes (HLA-DR, HLA-DP and HLA-DQ) which are selectively expressed 160 under normal conditions on the surface of antigen presenting cells (APCs), including B, 161 dendritic and mononuclear phagocyte cells. These molecules are non-covalently associated 162 heterodimers of two glycosylated, transmembrane polypeptide chains, the monomorphic 163 35-kDa α-chain and the highly polymorphic 28-kDa β-chain 36 . Both chains have an 164 extracellular portion composed of two domains (α1 and α2, or β1 and β2) that is anchored 165 on the cell membrane by short transmembrane and cytoplasmic domains ( Fig. 2c ). In the 166 classical scenario, the protease-derived foreign antigen peptides bind to MHC class II proteins 167 in the cleft formed by the α1 and β1 domains, and the complex is transported to the cell 168 surface 36, 37 . When antigenic peptides are not available, endogenous peptides such as the class 169 II associated invariant peptide (CLIP) substitute them and restore MHC class II dimer 170 stability 37 . The complex of HLA-DR and endocytosed peptides (usually 9-30 amino acids in 171 length), constitutes a ligand for the T-cell receptor (TCR) and plays a key role in the 172 presentation of foreign antigens to CD4 + T helper cells and immune surveillance 38, 39 . 173
174
Since the ultimate goal of our studies is to obtain insight on the zoonotic potential of H17N10, 175
we focused on the possible influence of HLA-DR on cellular susceptibility to H17. Hence, 176 taking advantage of the high expression of HLA-DR on certain human hematopoietic 177 carcinomas 40 , we further explored H17-PV tropism using a panel of human leukaemia and 178 lymphoma cell lines ( Fig. 2d ). We found that the Burkitt's lymphoma-derived Raji, Ramos and 179
BJAB B-lymphocytes and the B lymphoblastoid cells (B-LCL) show decreasing susceptibility, 180
in that order, to H17-PV. Kasumi-1 leukaemic cells showed marginal susceptibility in terms of 181 luciferase activity, while Molt-4 and HL-60 leukaemic cells, Jurkat T-cells, pro-monocytic THP-1 and U-937 cells, and primary B cells showed no susceptibility to the pseudotypes (Fig. 2d , 183 left Y axis). We hypothesised that the different susceptibility of the various cell types by H17-184 PV were due to disparate expression of HLA-DR, confirmed by qRT-PCR analysis for a non-185 polymorphic region of the α chain of HLA-DR on the same samples ( Fig. 2d , right Y-axis). The 186 presence of the HLA-DR heterodimer was also confirmed by flow cytometry with a FITC-187 conjugated monoclonal antibody (clone Tü36), which specifically binds to a monomorphic 188 epitope on the HLA-DR α/β complex and not the isolated α or β chains ( Fig. 2e cells correspondingly reduced the infection of H17-PV by 50% ( Fig. 2f) . 203
204
To determine if blocking attachment of virus to the HLA-DR ectodomain can prevent its entry, 205
Raji cells were incubated with increasing concentrations of a monoclonal antibody (mAb 206 Clone 302CT2.3.2) targeting a monomorphic, extracellular region of the HLA-DRA antigen 207 (HLA-DRA epitope: amino acids 48-75). The presence of the antibody significantly reduced, in 208 a dose-dependent manner, infection with H17-PV but not VSV-G-PV (Fig. 2g ). 209
210
We next sought to ascertain whether ectopic expression of HLA-DR was sufficient to increase 211 the susceptibility of non-APC, HEK293T/17, cells to the H17-PVs. HEK293T/17 cells were 212 transiently transfected with the DRA expression vector, alone or in combination with DRB1. 213
Surface expression of the α/β heterodimer was validated using immunofluorescence and flow 214 cytometry. Expression of either DRA or DRB1 alone resulted in marginal or no increase in 215 surface staining of HLA-DR or H17-PV infection (data not shown). In contrast, 1:1 co-216 expression of both DRA and DRB1 formed a functional α/β heterodimer on the cell surface in 217 approximately 47% of the cell population ( Fig. 2h and Supplementary material 4). This 218 suggests that both α and β chains are necessary for cell-surface expression, consistent with 219 previous studies 42, 43 . Transient over expression of HLA-DR in HEK293T/17 cells resulted in 220 significant infection by H17-PV. Infection was higher by more than two orders of magnitude 221 Taken together, HLA-DR is shown to function as a bona fide entry mediator for H17 but may 226 function with unknown factors that facilitate virus internalisation. Interaction between HLA-227 DR and H17 may trigger viral entry through canonical receptor-mediated endocytosis, but 228 could also trigger entry through an activation of cell signalling pathways that the virus 229 subverts to its advantage. Our finding therefore raises questions on the utility and possible 230 evolutionary advantage(s) that an APC-associated receptor would confer to H17N10 231 infectivity and broader fitness. Some viruses exploit cells of the immune system, such as 232 macrophages, B and dendritic cells, either as viral reservoirs or as "Trojan horses" to 233 penetrate the epithelial barriers 44, 45 . The measles virus for example, exploits macrophages or 234 dendritic cells, which traffic the virus to bronchus-associated lymphoid tissue or regional 235 lymph nodes, resulting in local amplification and subsequent systemic dissemination by 236 viremia 46 . A similar strategy employed by H17N10 could provide an explanation on why viral 237 RNA was detected in different organs and tissues in carrier S. lilium bats (i.e. lung, kidney, 238 liver, intestine) and why the virus fails to grow in vitro in cell lines developed from the same 239 tissues 1, 26 . The prototypic gammaherpesvirus, Epstein-Barr virus (EBV), employs resting B 240 cells as transfer vehicles for infection of epithelial cells 47 , and also uses the HLA-DR (β1 241 domain) as receptor in order both to enter B cells as well as to impair antigen presentation 242 (by sterically blocking the engagement of HLA-DR1 and the TCR Vα domain) 48, 49, 50 . It is 243 possible that through efficient binding to HLA-DR, H17N10 may have developed a means of 244 simultaneously accessing lymphoid cells and blocking T-cell responses. Such an immune 245 evasion mechanism could explain, at least partially, its survival and asymptomatic status in 246 carrier bats. With limited functional information available on the bat MHC-II, the biological 247 role of the host HLA-DR orthologue in the pathogenesis and transmission mechanisms of the 248 H17N10 virus remains obscure. 249
In this study we did not establish the stoichiometry of the HLA-DR: H17 engagement, or 250 clarify how the virus moves to sub-membranous regions and might hijack the receptor-251 mediated signalling pathway to promote its internalization. It is likely that the determinants 252 of viral entry in vivo are more complicated. We cannot rule out the use by H17N10 (as by 253 other bat-borne viruses, e.g. SARS CoV 51, 52 ) of more than one molecular species as (co-) 254 receptors. Nevertheless, the implication of this study is that H17N10 has the capacity to 255 enter human HLA-DR + cells and our work provides substantial evidence that the H17N10 256 virus has zoonotic potential. The current finding not only sheds light on the understanding 257 of BatIV host range, but also provides additional information on the evolution of influenza 258 A viruses. 259
Materials and methods 261

Cell lines, cell culture and treatment 262
Cell lines (complete description in Supplementary material 1) were kindly provided as supplemented with heat-inactivated 15% fetal bovine serum (Life Technologies), penicillin 283 (100 U/ml) and streptomycin (100 μg/ml; Invitrogen). All cells were maintained in a 284 humidified incubator at 37°C and 5% CO2 and were found free of mycoplasma contamination 285 on repeated testing with the MycoFluor Mycoplasma Detection Kit (Life Technologies, UK). 286
MDCK II cells were treated as previously 19 with the following modifications. MDCK II cells 287 were either treated with the endosomal acidification reagent ammonium chloride (1, 10 or 288 100 mM), or pre-treated with neuraminidase from Clostridium perfrigens for 2 h (1, 10 
Lentiviral pseudotype virus production and susceptibility assays 297
Pseudotypes expressing H17 and N10 genes were produced as described previously 32, 53 . 298
Briefly, the lentiviral packaging plasmid p8.91 54 , the pCSFLW firefly luciferase lentiviral 299 vector 55 or the GFP expressing vector pCSGW, the expression plasmids for H17 and/or N10 300 [vector pI.18 56 and the protease encoding plasmid pCAGGS-HAT (a kind gift by Eva Böttcher-301
Friebertshäuser, Philipps University of Marburg, Germany) were co-transfected using 302 polyethylenimine transfection reagent (Sigma Aldrich, UK) into HEK293T/17 cells, plated on 303 6-well Nunclon © plates (Thermo Fisher Scientific, UK). Supernatants were collected 48-72 h 304 post transfection and filtered through a 0.45 µm filter (Millipore, UK). To remove viral titer 305 bias between different PV stocks, pseudotypes were concentrated and (re-) titrated by serial 306 dilution. Concentration was carried out by ultra-centrifugation for 2 h at 25,000 rpm, 4°C in 307 the SW32 rotor of a L2-65B Beckman ultra-centrifuge. 308
Two-fold serial dilutions of PV-containing supernatant were performed as previously 309 described 32 using white 96-well Nunclon © plates (Thermo Fisher Scientific, UK). 310
Subsequently, approximately 1x10 4 (for adherent) and 3 x10 4 cells (for suspension) cells were 311 added in 50 µl of medium per well. Plates were incubated for 48 h, after which 50 µl of 312
Bright-Glo™ substrate (Promega, UK) was added. Luciferase readings were conducted with a 313 luminometer (FLUOstar OPTIMA, BMG Labtech) after a 5-minute incubation period and 314 luciferase reading recorded in relative luminescence units (RLU). Data were normalized using 315 Δ-env and cell-only measurements and expressed as RLU/ml. 316
Plasmids and transfections 317
Mammalian expression plasmids (pcDNA3.1 + /C -(K)DYK) for HLA-DRA (NM_019111) and 318 HLA-DRB1 (NM_001243965) were purchased from GenScript (Piscataway, NJ; USA). 319
HEK293T/17 cells at sub-confluence in 6-well plates or 100 mm dishes were transfected 320 with HLA-DRA plasmid or HLA-DRB1 plasmid or a 1:1 combination of both using the 321
Lipofectamine 3000 transfection reagent (Thermo Fisher Scientific, UK) according to 322 manufacturer instructions. 48 h after transfection, cells were used either for 323 immunofluorescence analysis, or for FACS analysis (cell-surface staining) or for infection 324 with PV. Under the experimental conditions, the transfection efficiency in either plate/dish, 325 as assessed by the GFP expression of a co-transfected GFP-expressing control plasmid, was 326 >70% under microscopic observation. For HLA-DR stably over expressing cells, PakiTO3 327 cells were transfected with both HLA-DR plasmids and then selected with neomycin (500 328 µg/ml). Single clones were analysed for expression of the over expressed proteins. 329
RNA isolation for microarray analysis 330
Total RNA was isolated from biological triplicates of early and late passage MDCK from T25 331 flasks that had been seeded with 8 x 10 5 cells and allowed to become confluent and polarize 332 over 4 days in culture cells using a Ribopure kit (Ambion, Austin, TX). Acquired RNA was 333 precipitated with EtOH and subsequently purified employing columns, procedures and 334 reagents from an RNEasy kit (Qiagen, Germantown, MD) and resuspended in RNAse-free H2O. 335
Complementary DNA and RNA synthesis were performed according to Affymetrix Expression 336 Analysis protocols (see www.affymetrix.com). Briefly, double-stranded cDNA was synthesized 337 from 5 μg of total RNA using the Superscript double-stranded cDNA synthesis kit (Invitrogen). 338
Following phenol/chloroform extraction and ethanol precipitation, a biotin-labeled in-vitro 339 transcription reaction was carried out using the cDNA template (Enzo Life Sciences, 340
Farmingdale, NY). Fifteen micrograms of cRNA was fragmented for hybridization to 341 were collected and assessed by quantitative respectively. 360 In order to evaluate the interaction of HLA-DR with H17 we used the HLA DRA mAb 361 (302CT2.3.2), which is generated from mice immunized with a KLH conjugated synthetic peptide between 48-75 amino acids from human HLA-DRA. After a 1 h pre-incubation with 363 increasing concentrations of the antibody in normal growth media, Raji cells (3x10 4 ) were 364 infected for 24-48 h with H17-or VSV-G-PV. 365 366
Western blot analysis 367
Washed cells were lysed on ice with lysis buffer [0.5% NP40 in PBS with 10 mM Tris-HCl, pH 368 7.4 supplemented with Halt Protease Inhibitor mixture EDTA-free (Thermo Fisher Scientific 369
UK)] and protein was quantified by the BCA assay kit (Thermo Fisher Scientific, UK). 20-50 µg 370 of protein was electrophoresed on a 4-15% sodium dodecylsulfate polyacrylamide gel, 371 alongside a protein ladder (Precision Plus Protein Dual Colour Standards, Bio-Rad) and 372 immunoblotted with the following antibodies using standard procedures: mouse monoclonal 373 anti-HLA-DRA (1:1000; Clone: 302CT2, Enzo Life Sciences, UK) or rabbit monoclonal a-tubulin 374 (1:2000; Cell signalling Technology, UK) antibodies. The membranes were then washed with 375 PBS for three times and incubated with goat anti-rabbit or donkey anti-mouse secondary 376 antibodies (LI-COR) in the dark for 1 h. Scanning was then carried out using the Odyssey 377
Imaging system (LI-COR). 378
379
Immunofluorescence 380
Transfected cells with HLA-DRA and -DRB1 expression plasmids or with the empty plasmid 381 were seeded onto glass cover slips at 5x10 4 cells/ml in 6 well plates overnight and were fixed 382 with 4% paraformaldehyde in PBS for 30 minutes at room temperature (RT). Fixed cells were 383 washed with PBS and permeabilised with 1% Triton X-100 in PBS for 10 minutes. After 384 washing with PBS, the cover slips were incubated with a mouse HLA-DRA mAb (169-1B5.2; 385
Bio-Techne Ltd) targeting a monomorphic general framework determinant of HLA-DR Class II 386 antigen, diluted in 5% BSA/PBS for 1 hr at RT. The cover slips were then washed 3X with 387 0.02% Tween 20 and 1% BSA in PBS, followed by incubation with Alexafluor 488 conjugated 388 anti-mouse (Thermo Fisher Scientific, UK) for 30 minutes at RT. After washing 3X with 0.02% 389 Tween 20 and 1% BSA in PBS, the cover slips were mounted using Prolong Gold containing 390 DAPI (Invitrogen). Images were acquired on EVOS fluorescent microscope (EVOS FL imaging 391 system; Life Technology, USA). Experiments were carried out twice. MasterMix (Eurogentec) was added to the cDNA (5 μl for every 2 μl of cDNA). The following 412 primers were used: for canine 413 Reverse: 5'-TCTGGAGGTACATTGGTGTTCG-3'), for canine DLA-DRB1 (Forward: 5'-414 AGCACCAAGTTTGACAAGC-3', Reverse: 5-AAGAGCAGACCCAGGACAAAG-3'). The following 415 amplification conditions were used: 95°C for 5 minutes; 40 cycles of 95°C for 15 seconds, 57°C 416 for 20 seconds, and 72°C for 20 seconds; 95°C for 15 seconds; 60°C for 15 seconds; and 95°C 417 for 15 seconds. The output Ct values and dissociation curves were analysed using SDS v2.3 418 and RQ Manager v1.2 (Applied Biosystems). Gene expression data were normalized against 419 the housekeeping gene GAPDH, and compared with the mock controls using the comparative 420 CT method (also referred to as the 2 -ΔΔCT method 58 ). Absolute copy numbers of HLA-DRA in -26, 62-85, 97-115, 121-142, 154-177, 183-205, 270-293, 305-326, 333-355, 361-379, 400-420, 426- 
